Neuphoria Therapeutics (NASDAQ:NEUP) Trading 17.7% Higher – Should You Buy?

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) shot up 17.7% on Thursday . The stock traded as high as $4.20 and last traded at $3.92. 7,610,379 shares were traded during mid-day trading, an increase of 8,538% from the average daily volume of 88,104 shares. The stock had previously closed at $3.33.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Monday, June 1st. HC Wainwright cut shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Neuphoria Therapeutics presently has an average rating of “Hold” and an average target price of $21.00.

Neuphoria Therapeutics Trading Up 17.7%

The stock has a market capitalization of $21.17 million, a PE ratio of -0.35 and a beta of 0.74. The business’s 50-day moving average is $4.31 and its two-hundred day moving average is $4.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.47. On average, analysts predict that Neuphoria Therapeutics Inc. will post -4.07 EPS for the current year.

Hedge Funds Weigh In On Neuphoria Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AdvisorShares Investments LLC grew its position in Neuphoria Therapeutics by 129.1% in the fourth quarter. AdvisorShares Investments LLC now owns 134,194 shares of the company’s stock valued at $521,000 after acquiring an additional 75,631 shares in the last quarter. Ikarian Capital LLC acquired a new position in shares of Neuphoria Therapeutics during the fourth quarter worth $184,000. ADAR1 Capital Management LLC acquired a new position in shares of Neuphoria Therapeutics during the fourth quarter worth $116,000. Diadema Partners LP boosted its stake in shares of Neuphoria Therapeutics by 133.1% in the fourth quarter. Diadema Partners LP now owns 50,000 shares of the company’s stock valued at $194,000 after purchasing an additional 28,548 shares during the period. Finally, FNY Investment Advisers LLC purchased a new position in shares of Neuphoria Therapeutics in the fourth quarter valued at $102,000. 15.90% of the stock is owned by institutional investors and hedge funds.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.